SCHEMBL14746218

SCHEMBL14746218

CCc1c(O)cc(=O)[nH]c1-c1ccc2c(c1)c(Cl)cn2C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.33
CHRNA7 P36544 2/20 0.32
BRD4 O60885 1/20 0.32
NR4A2 P43354 4/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
GAA P10253 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
POLB P06746 1/20 0.30
RECQL P46063 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
PTGES O14684 1/20 0.30
ALOX5 P09917 1/20 0.30
RXRA P19793 1/20 0.30
RXRB P28702 1/20 0.30
DRD1 P21728 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14744717 0.84 XDH (0.41)
SCHEMBL14740900 0.80 NR4A2 (0.33) MEN1KMT2ACHRNA7NR4A2PTGES
SCHEMBL16428430 0.78 MAPT (0.38) HTTMEN1KMT2ABRD4CYP1A2
SCHEMBL16428798 0.74 MEN1 (0.38) HTTMEN1KMT2ACYP1A2CYP3A4
SCHEMBL16428410 0.74 USP7 (0.48) BRD4
SCHEMBL16441019 0.72 F2RL3 (0.35)
SCHEMBL16428837 0.72 CHRM1 (0.38) HTT
SCHEMBL14745063 0.72 ERCC1 (0.54) BRD4
SCHEMBL14745065 0.72 MAPT (0.41) BRD4
SCHEMBL16428629 0.72 HSP90AA1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP HTT 4310/4885MEN1 4630/4885KMT2A 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.